Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CLN-049

Bispecific antibody · Immune activation, directed at FLT3 tyrosine kinase receptor (FLT3) and CD3 · developed by Cullinan Therapeutics

Phase 1 Most advanced trial

CGEM Developer

1 Registered trials

What is CLN-049?

CLN-049 is a humanized, Fc-silenced IgG1-based bispecific antibody that binds the FLT3 receptor tyrosine kinase on tumor cells and CD3 on cytotoxic T-lymphocytes. By bridging the two, it redirects T cells to kill FLT3-expressing cells. It is being studied in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Bispecific antibody
Targets: FLT3 tyrosine kinase receptor (FLT3), CD3
Mechanism: Immune activation, directed at FLT3 tyrosine kinase receptor (FLT3) and CD3
Pathways: T-cell mediated cytotoxicity of FLT3-expressing tumor cells
Therapy area: Oncology
Developer: Cullinan Therapeutics Inc. (CGEM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05143996	Phase 1	Relapsed/Refractory Acute Myeloid Leukemia (AML)	Recruiting	CGEM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)

Other drugs acting on FLT3

Gilteritinib FDA approved Midostaurin FDA approved Pexidartinib FDA approved BMF-500 Phase 1 CDX-301 Phase 2 Dapolsertib Phase 1/2 Lomonitinib Phase 2/3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CGEM page.

Follow CGEM, the company behind CLN-049

See CGEM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CGEM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z